GLP-1R agonists’ type 2 diabetes and obesity market to reach $125 billion in 7MM by 2033: GlobalData Read more
GLP-1R agonists clinical trial design needs to be improved to reassure drugs’ benefits: GlobalData Read more
Glenmark Pharma launches triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India Read more